The drug is now in Phase 2 clinical trials in patients with Alzheimer’s and Fragile X syndrome
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer’s disease.
Preclinical research found that the drug — called BPN14770 — deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to nerve cells.
Recent studies find Alzheimer’s may develop without dementia in nearly 25% of healthy 80-year-old patients, suggesting the body may turn to compensatory mechanisms to maintain the nervous system.
BPN14770, under development by Tetra Therapeutics, could help activate these mechanisms that support nerve health and prevent dementia, even with the progression of Alzheimer’s.
Its benefits could also translate to Fragile X syndrome, developmental disabilities and schizophrenia, researchers say.
“Such observations imply that Alzheimer’s pathology can be tolerated by the brain to some extent due to compensatory mechanisms operating at the cellular and synaptic levels,” said Ying Xu, MD, PhD, co-lead investigator and research associate professor in the UB School of Pharmacy and Pharmaceutical Sciences.
“Our new research suggests that BPN14770 may be capable of activating multiple biological mechanisms that protect the brain from memory deficits, neuronal damage and biochemical impairments.”
The study, published on Sept. 5 in The Journal of Pharmacology and Experimental Therapeutics, was also led by James M. O’Donnell, PhD, dean and professor of the UB School of Pharmacy and Pharmaceutical Sciences. Mark E. Gurney, PhD, chairman and chief executive officer of Tetra Therapeutics, based in Grand Rapids, Michigan, collaborated on the research.
Guarding memory against toxic proteins
The research, conducted in mice, discovered that BPN14770 inhibits the activity of phosphodiesterase?4D (PDE4D), an enzyme that plays a key role in memory formation, learning, neuroinflammation and traumatic brain injury.
PDE4D lowers cyclic adenosine monophosphate (cAMP) — a messenger molecule that signals physiological changes such as cell division, change, migration and death — in the body, leading to physical alterations in the brain.
cAMP has numerous beneficial functions, including improved memory. By inhibiting PDE4D, BPN14770 increases cAMP signaling in the brain, which ultimately protects against the toxic effects of amyloid beta.
“The role of PDE4D in modulating brain pathways involved in memory formation and cognition, and the ability of our PDE4D inhibitor to selectively enhance this process, has been well studied,” said Gurney. “We are very excited by our colleagues’ findings, which now suggest a second protective mechanism of action for BPN14770 against the progressive neurological damage associated with Alzheimer’s disease.”
“Developing effective drugs for memory deficits associated with Alzheimer’s disease has been challenging,” said O’Donnell. “BPN14770 works by a novel mechanism to increase cyclic AMP signaling in the brain, which has been shown to improve memory. The collaborative project has led to clinical trials that will begin to test its effectiveness.”
Tetra Therapeutics is conducting Phase 2 clinical trials of BPN14770 in patients with early Alzheimer’s and adults with Fragile X syndrome, a genetic disorder that causes intellectual and developmental disabilities.
Results of previous Phase 1 studies in healthy elderly volunteers suggest the drug benefits working, or immediate, memory. Animal studies found that BPN14770 has the potential to promote the maturation of connections between neurons, which are impaired in patients with Fragile X syndrome, as well as protect these connections, which are lost in patients with Alzheimer’s.
“There has been enormous interest in our ongoing Phase 2 trial of BPN14770 in 255 patients with early Alzheimer’s, and we are hopeful this study will show an impact of PDE4D modulation in this disease. Topline results are expected mid-2020,” said Gurney.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimer's caretaker helps open new adult daycare facility in Georgetownon November 29, 2019 at 8:30 pm
GEORGETOWN, Texas — Vic Figurelli's wife, Camille, died in 2016. She was diagnosed with Alzheimer's in 2011. Between those years, Vic had to make tough decisions to take care of Camille, including ...
- The 10 states with the highest rates of Alzheimer’s diseaseon November 29, 2019 at 11:30 am
Alzheimer’s disease is the sixth leading cause of death in the United States, with death rates on the rise.
- Her husband died of Alzheimer's. Now she's giving back to otherson November 29, 2019 at 4:04 am
Her husband died from Alzheimer's disease in 1999. Since then, this woman has been on a mission to give back to others. She chooses to honor her late husband with a ...
- Calorie restriction slows age-related microbiota changes in an Alzheimer’s disease model in female miceon November 29, 2019 at 3:15 am
Alzheimer’s disease (AD) affects an estimated 5.8 million Americans, and advanced age is the greatest risk factor. AD patients have altered intestinal microbiota. Accordingly, depleting intestinal ...
- Lying helped my family live with Alzheimer'son November 29, 2019 at 1:00 am
“We got $5 million for the house, Dad,” I said to my father. I was lying. However, as the angst washed from his face, I knew that this untruth — what Alzheimer’s experts call a compassionate lie — was ...
- HEARING VIBES: Hearing Loss and Alzheimers Some Startling Comparisonson November 28, 2019 at 11:00 pm
In a visit to a doctor’s office recently, I saw a startling poster on the wall. It was entitled “Untreated Hearing Loss and Alzheimers Disease.” I was shocked to see the symptom similarities between ...
- Successful Aging: What you need to know about Alzheimer’s diseaseon November 28, 2019 at 12:08 pm
November was Alzheimer’s Awareness month, which was designated by President Reagan in 1983. Given the importance of the topic, here are some distilled facts (or myths) in the form of a true-false quiz ...
- Will a Treatment for Alzheimer’s Ever Be Found?on November 28, 2019 at 9:24 am
One way to find what’s broken is through genetics, but the first wave of genetic studies in the 80s and 90s only had the technical capabilities to investigate Alzheimer’s cases that run in families, ...
- New York City 12-year-old honored by Marvel for helping people with Alzheimer'son November 27, 2019 at 2:15 pm
NEW YORK -- A New York City girl launched an initiative to help people with Alzheimer's disease, and now her good deed is getting the attention of Marvel. 12-year-old Hailey Richman is being honored ...
- Lawyers say federal death row prisoner has Alzheimer'son November 27, 2019 at 9:55 am
WASHINGTON — Lawyers for a federal death row inmate convicted of rape and murder have asked a federal judge to halt his scheduled execution next month because the prisoner has Alzheimer's disease and ...
via Bing News